Moderate Reduction of γ-Secretase Attenuates Amyloid Burden and Limits Mechanism-Based Liabilities
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Although γ-secretase is recognized as a therapeutic target for Alzheimer's disease, side effects associated with strong inhibition of this aspartyl protease raised serious concerns regarding this therapeutic strategy. However, it is not known whether moderate inhibition of this enzyme will allow dissociation of beneficial effects in the CNS from mechanism-based toxicities in the periphery. We tested this possibility by using a series of mice with genetic reduction of γ-secretase (levels ranging from 25 to 64% of control mice). Here, we document that even 30% reduction of γ-secretase can effectively ameliorate amyloid burden in the CNS. However, global reduction of this enzyme below a threshold level increased the risk of developing squamous cell carcinoma as well as abnormal proliferation of granulocytes in a γ-secretase dosage-dependent manner. Importantly, we demonstrate that there exists a critical γ-secretase level that reduces the risk of amyloidosis in the CNS and limits tumorigenesis in epithelia. Our findings suggest that moderate inhibition of γ-secretase represents an attractive anti-amyloid therapy for Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Aph-1, Pen-2, and Nicastrin with Presenilin Generate an Active γ-Secretase Complex
De Strooper, B. (2003) · Neuron · doi:10.1016/s0896-6273(03)00205-8 · Cited by 965 · cited 1×
“-Secretase, an aspartyl protease comprising presenilin (PS), nicastrin (Nct), anterior pharynx defective-1 (Aph-1), and PS enhancer-2 (Pen-2) (De Strooper, 2003), is an unusual enzyme required for the regulated intramembranous proteolysis of a growing list of type I transmembrane proteins, such as…”
BackgroundSaura, C. A., Choi, S.-Y., Beglopoulos, V., Malkani, S., Zhang, D., Rao, B. S. S., Chattarji, S., Kelleher, R. J., Kandel, E. R., Duff, K., et al. (2004) · Neuron · doi:10.1016/s0896-6273(04)00182-5 · Cited by 757 · cited 2×
“-Secretase functions as a tumor suppressor Although it remains unclear as to the consequences of chronic reduction of -secretase activity in vivo, outcomes from studies of conditional deletion of PS in the forebrain were interpreted to support the view that partial loss of PS function in CNS may contribute to memory l…”
BackgroundElchuri, S., Oberley, T. D., Qi, W., Eisenstein, R. S., Jackson Roberts, L., Van Remmen, H., Epstein, C. J., & Huang, T.-T. (2005) · Oncogene · doi:10.1038/sj.onc.1208207 · Cited by 667 · cited 1×
“…oncogene that regulates the tumor suppressor PTEN (phospha- tase and tensin homolog) (Kim et al., 2005), and superoxide dismutase 1, associated with autosomal dominant familial amyotrophic lateral sclerosis (Rosen et al., 1993), when deleted in mice induces liver carcinoma (Elchuri et al., 2004).”
BackgroundBarten, D. M., Guss, V. L., Corsa, J. A., Loo, A., Hansel, S. B., Zheng, M., Munoz, B., Srinivasan, K., Wang, B., Robertson, B. J., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.075408 · Cited by 159 · cited 2×
“Moreover, discrepancies appear to exist between different inhibitors of -secretase; one inhibitor, BMS2999897, did not show the same side effects (Barten et al., 2005) as that of LY411575 (Milano et al., 2004; Wong et al., 2004).”
Background
Cited by
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061
“Conditional PS1 deletions result in impairments in memory and in hippocampal synaptic plasticity (Saura et al. 2004), whereas nicastrin heterozygote knockout mice develop skin tumors (Li et al. 2007b).”
BackgroundSelf-citationVassar, R., Kovacs, D. M., Yan, R., & Wong, P. C. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3657-09.2009 · Cited by 577
Self-citationThe Many Substrates of Presenilin/γ-Secretase
Haapasalo, A., & Kovacs, D. M. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-101065 · Cited by 458
Coric, V., van Dyck, C. H., Salloway, S., Andreasen, N., Brody, M., Richter, R. W., Soininen, H., Thein, S., Shiovitz, T., Pilcher, G., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.2194 · Cited by 374
A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system
Bateman, R. J., Siemers, E. R., Mawuenyega, K. G., Wen, G., Browning, K. R., Sigurdson, W. C., Yarasheski, K. E., Friedrich, S. W., DeMattos, R. B., May, P. C., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21623 · Cited by 322
Metadata
- Authors
- Li, T., Wen, H., Brayton, C., Laird, F. M., Ma, G., Peng, S., Placanica, L., Wu, T. C., Crain, B. J., Price, D. L., Eberhart, C. G., & Wong, P. C.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2007-10-03
- Volume
- 27
- Issue
- 40
- Pages
- 10849-10859
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2033043320
- Cited by
- 80
- References
- 5
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.